Join        Login             Stock Quote

Bristol Myers Squibb (BMY) 4Q Earnings Preview

 January 23, 2013 03:44 PM

(By Balachander) Bristol Myers Squibb Co. (NYSE: BMY) is expected to report lower earnings for the fourth quarter when the pharmaceutical products company reports results on Thursday.

Wall Street analysts, on average, expect BMY's earnings per share to fall 19 percent to 43 cents and revenue to decline 24 percent to $4.15 billion for the three month period.

BMO Capital Markets expects slightly lower EPS of $0.41 owing to the lack of R&D tax credit in 2012 and in-line revenue of $4.12 billion.

The company's principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide to treat hypertension and diabetic nephropathy; Eliquis to treat venous thromboembolic disorders and stroke prevention in atrial fibrillation

[Related -Bristol-Myers (BMY): Blockbusters Ahead?]

"We expect a mostly in-line quarter, but the focus of the call will likely be on the launch progress of Eliquis," BMO analyst Alex Arfaei wrote in a note. "Investors will look for updates on access, a more precise US launch date, and the company's longer-term outlook."

Based on Eliquis's best-in-class label and launch price, Arfaei does not anticipate significant access barriers in the US. Moreover, the analyst expects the US launch by the end of January/mid-February.

"Other areas of focus include secondary growth drivers Yervoy, Sprycel and Orencia, and we expect all will meet or exceed expectations," the analyst said.

Arfaei said investors will look for signs of improvement from the Exenatide franchise (from the Amylin acquisition) as a result of improved access and promotion efforts, and updates on pipeline products, such as Dapa in the US, and incremental anti-PD1 data in 2013.

[Related -Merck & Co., Inc. (MRK), Pfizer Inc. (PFE) and Bristol Myers Squibb Co. (BMY) : The Rebound May Be Over For Big Pharma]

For the full year, the company is projected to earn $1.96 a share on revenue of $17.56 billion.

During the current month, five analysts have recommended BMY as "Strong Buy" and two analysts gave a "Buy" rating,  while 12 analysts have a "Hold" rating on the stock. There is no analyst who recommends "Sell" on the stock.

In the preceding third quarter, Bristol Myers posted a GAAP loss of 43 cents a share versus a profit of 56 cents last year. Non-GAAP EPS of 41 cents were 33 percent lower than the year-ago period. Sales dropped 30 percent to $3.74 billion following the U.S. patent expiration of Avapro/Avalide in March 2012 and Plavix in May 2012.

Over the past year, shares of BMY have been trading between $30.64 and $36.34.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageAutomating Ourselves To Unemployment

In this current era of central planning, malincentives abound. We raced to frack as fast we could for the read on...

article imageFed: Waiting For June… Or Godot?

The Federal Reserve left interest rates unchanged yesterday, as widely expected. But the possibility of a read on...

article imageThe Single Best Place To Invest Your Money For Retirement

It was never supposed to be this daunting. At least that's what we were read on...

article imageNegative Blowback From Negative Interest Rates

The Federal Reserve is widely expected to leave interest rates unchanged today. But perhaps standing pat read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.